GPCR Crystallization via IC2 Insertion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for crystallizing family C G-protein coupled receptors (GPCRs) face challenges in achieving stable and functional crystal structures, which are essential for understanding their physiological processes and drug development, due to difficulties in maintaining the native conformation and activity of these receptors during the crystallization process.
Innovation Solution
A fusion protein is created by combining the TM1, TM2, and TM3 regions of a family C GPCR with a stable, folded protein insertion, such as lysozyme, and the TM4, TM5, TM6, and TM7 regions, allowing for crystallization and maintaining the receptor's activity, using methods like bicelle or lipidic cubic phase crystallization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If family C GPCRs are directly crystallized using conventional methods, then crystal formation may occur, but the receptor's native conformation and activity are lost or destabilized
Solution Approach 1:
A stable, folded protein (such as lysozyme or T4 lysozyme) is inserted into the intracellular loop 2 (ICL2) of the GPCR as an intermediary element. This inserted protein acts as a mediator that provides structural stability and promotes crystal lattice formation while preserving the native conformation of the receptor's transmembrane and extracellular domains. The inserted protein serves as a crystallization scaffold that enables crystal formation without disrupting the functional architecture of the GPCR.
Solution Approach 2:
The crystallization approach uses a composite structure combining the GPCR with a stable folded protein domain. This composite fusion protein integrates the functional GPCR regions (transmembrane domains and extracellular regions) with a structurally robust protein insert, creating a hybrid molecule that possesses both the biological activity of the GPCR and the crystallization propensity of the inserted stable protein.
2Ease of manufacture
If the GPCR structure is modified to facilitate crystallization, then crystal formation improves, but the native conformation and activity may be compromised
Solution Approach 1:
The structural modification is localized specifically to the intracellular loop 2 (ICL2) region, which is chosen because it is a flexible loop region that can accommodate the inserted stable protein without disrupting the rigid transmembrane helices or the extracellular agonist-binding domain. This localized insertion provides crystallization capability while preserving the native conformation and activity of the critical functional regions.
Solution Approach 2:
The stable folded protein inserted into ICL2 serves as an intermediary that bridges the gap between the GPCR's functional requirements and crystallization requirements. It provides the necessary structural framework for crystal lattice formation while allowing the GPCR's active sites and transmembrane domains to maintain their native configurations.
3Productivity
If conventional crystallization methods are used, then some crystal structures may be obtained, but the functional activity and physiological relevance are reduced
Solution Approach 1:
The stable folded protein is pre-inserted into the GPCR structure before the crystallization process begins. This preliminary structural preparation ensures that the receptor is in a conformationally stable state that favors crystal lattice formation, thereby increasing the efficiency of crystal structure determination while preserving physiological relevance.
Solution Approach 2:
The inserted stable protein acts as a mediator that facilitates crystal packing interactions without interfering with the GPCR's ligand-binding site or signal transduction capability. This allows obtaining crystal structures that reflect the native physiological conformation while improving crystallization efficiency.
Data Source
AI summary
Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising, from N-terminus to C-terminus: a) a first portion of a family C G-protein coupled receptor (GPCR), wherein the first portion comprises the TM1, TM2 and TM3, regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, wherein the second portion comprises the TM4, TM5 TM6 and TM7 regions of the GPCR.